Published in Clinical Oncology Week, November 21st, 2005
This compares with a net loss of $24.0 million, or $0.54 per share, for the same quarter in 2004. The increase in net loss in the current quarter compared to the third quarter of 2004 can be attributed to increased operating losses, resulting in part from greater expenditures on our GVAX vaccine for prostate cancer program. Cell Genesys ended the quarter with approximately $102.4 million in cash, cash equivalents and short-term investments.
In addition, Cell Genesys held approximately 6.0 million shares of its former...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.